These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33649568)

  • 1. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4
    Sugata K; Matsunaga Y; Yamashita Y; Nakatsugawa M; Guo T; Halabelian L; Ohashi Y; Saso K; Rahman MA; Anczurowski M; Wang CH; Murata K; Saijo H; Kagoya Y; Ly D; Burt BD; Butler MO; Mak TW; Hirano N
    Nat Biotechnol; 2021 Aug; 39(8):958-967. PubMed ID: 33649568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
    Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
    Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule.
    Cohen WM; Pouvelle-Moratille S; Wang XF; Farci S; Munier G; Charron D; Ménez A; Busson M; Maillère B
    J Immunol; 2006 May; 176(9):5401-8. PubMed ID: 16622007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients.
    Rockinger GA; Guillaume P; Cachot A; Saillard M; Speiser DE; Coukos G; Harari A; Romero PJ; Schmidt J; Jandus C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II tetramers engineered for enhanced binding to CD4 improve detection of antigen-specific T cells.
    Dileepan T; Malhotra D; Kotov DI; Kolawole EM; Krueger PD; Evavold BD; Jenkins MK
    Nat Biotechnol; 2021 Aug; 39(8):943-948. PubMed ID: 33941928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
    Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
    Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
    Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of CD4
    Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
    Front Immunol; 2020; 11():602014. PubMed ID: 33658991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.
    Grifoni A; Moore E; Voic H; Sidney J; Phillips E; Jadi R; Mallal S; De Silva AD; De Silva AM; Peters B; Weiskopf D; Sette A
    Front Immunol; 2019; 10():1568. PubMed ID: 31333679
    [No Abstract]   [Full Text] [Related]  

  • 13. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
    Zhao Y; Zheng Z; Khong HT; Rosenberg SA; Morgan RA
    J Immunother; 2006; 29(4):398-406. PubMed ID: 16799335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide-MHC Class II Multimers.
    Holland CJ; Dolton G; Scurr M; Ladell K; Schauenburg AJ; Miners K; Madura F; Sewell AK; Price DA; Cole DK; Godkin AJ
    J Immunol; 2015 Dec; 195(12):5827-36. PubMed ID: 26553072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions.
    Jönsson P; Southcombe JH; Santos AM; Huo J; Fernandes RA; McColl J; Lever M; Evans EJ; Hudson A; Chang VT; Hanke T; Godkin A; Dunne PD; Horrocks MH; Palayret M; Screaton GR; Petersen J; Rossjohn J; Fugger L; Dushek O; Xu XN; Davis SJ; Klenerman D
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5682-7. PubMed ID: 27114505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
    Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
    Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
    Lee MN; Meyerson M
    Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
    Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.